Philippe Tessier studied at Laval University, the John Curtin School of Medical Research (Australian National University) and the University of Adelaide, followed by a post-doctoral fellowship at the Imperial Cancer Research Fund (United Kingdom). He has been a researcher at the Centre de recherche du CHU de Québec – Laval University since 1999, and a professor at the Department of Microbiology-Infectiology and Immunology of the Laval University School of Medicine.

Research Projects

Professor Tessier studies the biological activities of the proteins S100A8 and S100A9, two small proteins expressed by neutrophils, monocytes, and activated endothelial and epithelial cells. These proteins are secreted during inflammation and activate the immune response. His research indicates that S100A8 and S100A9 have opposite functions: S100A8 is anti-inflammatory and inhibits myeloid cell differentiation, while S100A9 is pro-inflammatory and induces the differentiation of precursors of neutrophils and monocytes. He studies the roles of these proteins in autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease, in immune responses to solid tumors, and in the differentiation of leukemia cells.

Auto-inflammatory diseases are monogenic orphan diseases (<10,000 cases per syndrome worldwide) usually caused by defects in the genes regulating innate immunity. These diseases are characterized by recurrent, unprovoked inflammation (fever, abdominal pain, rash, arthralgia). High plasma concentrations of S100A8 and S100A9 are often found in patients with auto-inflammatory diseases. In collaboration with Professor Martin Pelletier and Dr. Anne-Laure Chetaille, Prof. Tessier is currently studying the roles of S100A8 and S100A9 in these diseases, to develop a diagnostic test to facilitate the treatment of these patients.

CHUL
2705, boulevard Laurier
RC-709
Québec, Québec
Canada G1V 4G2
+1 418-525-4444, extension 47607
+1 418-654-2715
philippe.tessier@crchudeq...

Latest news

Data not available

57 entries « ‹ 1 of 6 › »

Defrene J, Berrazouane S, Esparza N, Page N, Cote MF, Gobeil S, Aoudjit F, Tessier PA

Deletion of S100a8 and S100a9 Enhances Skin Hyperplasia and Promotes the Th17 Response in Imiquimod-Induced Psoriasis.

Journal Article

J Immunol, 206 (3), pp. 505-514, 2021, ISSN: 0022-1767.

Abstract | Links:

Poubelle PE, Page N, Longchamps MP, Sampaio Moura N, Beck DB, Aksentijevich I, Tessier PA, Pelletier M

The use of leukocytes' secretome to individually target biological therapy in autoimmune arthritis: a case report.

Journal Article

Clin Transl Med, 8 (1), pp. 19, 2019, ISSN: 2001-1326.

Abstract | Links:

Jeong H, Kim S, Hong BJ, Lee CJ, Kim YE, Bok S, Oh JM, Gwak SH, Yoo MY, Lee MS, Chung SJ, Defrene J, Tessier P, Pelletier M, Jeon H, Roh TY, Kim B, Kim KH, Ju JH, Lee YJ, Kim DW, Kim IH, Kim HJ, Park JW, Lee YS, Lee JS, Cheon GJ, Weissman IL, Chung DH, Jeon YK, Ahn GO

Tumor-Associated Macrophages Enhance Tumor Hypoxia and Aerobic Glycolysis.

Journal Article

Cancer Res, 79 (4), pp. 795-806, 2019, ISSN: 0008-5472.

Abstract | Links:

Cesaro A, Defrene J, Lachhab A, Page N, Tardif MR, Al-Shami A, Oravecz T, Fortin PR, Daudelin JF, Labrecque N, Aoudjit F, Pelletier M, Tessier PA

Enhanced myelopoiesis and aggravated arthritis in S100a8-deficient mice.

Journal Article

PLoS ONE, 14 (8), pp. e0221528, 2019.

Abstract | Links:

Fujita Y, Khateb A, Li Y, Tinoco R, Zhang T, Bar-Yoseph H, Tam MA, Chowers Y, Sabo E, Gerassy-Vainberg S, Starosvetsky E, James B, Brown K, Shen-Orr SS, Bradley LM, Tessier PA, Ronai ZA

Regulation of S100A8 Stability by RNF5 in Intestinal Epithelial Cells Determines Intestinal Inflammation and Severity of Colitis.

Journal Article

Cell Rep, 24 (12), pp. 3296-3311.e6, 2018.

Abstract | Links:

Pelletier M, Simard JC, Girard D, Tessier PA

Quinoline-3-carboxamides such as tasquinimod are not specific inhibitors of S100A9.

Journal Article

Blood Adv, 2 (10), pp. 1170-1171, 2018, ISSN: 2473-9529.

| Links:

Joly P, Marshall JC, Tessier PA, Masse C, Page N, Frenette AJ, Khazoom F, Le Guillan S, Berthiaume Y, Charbonney E

S100A8/A9 and sRAGE kinetic after polytrauma; an explorative observational study.

Journal Article

Scand J Trauma Resusc Emerg Med, 25 (1), pp. 114, 2017.

Abstract | Links:

Laouedj M, Tardif MR, Gil L, Raquil MA, Lachaab A, Pelletier M, Tessier PA, Barabe F

S100A9 induces differentiation of acute myeloid leukemia cells through TLR4.

Journal Article

Blood, 129 (14), pp. 1980-1990, 2017, ISSN: 0006-4971.

Abstract | Links:

Rousseau LS, Pare G, Lachhab A, Naccache PH, Marceau F, Tessier P, Pelletier M, Fernandes M

S100A9 potentiates the activation of neutrophils by the etiological agent of gout, monosodium urate crystals.

Journal Article

J Leukoc Biol, 102 (3), pp. 805-813, 2017, ISSN: 0741-5400.

Abstract | Links:

Yoon J, Leyva-Castillo JM, Wang G, Galand C, Oyoshi MK, Kumar L, Hoff S, He R, Chervonsky A, Oppenheim JJ, Kuchroo VK, van den Brink MR, Malefyt RW, Tessier PA, Fuhlbrigge R, Rosenstiel P, Terhorst C, Murphy G, Geha RS

IL-23 induced in keratinocytes by endogenous TLR4 ligands polarizes dendritic cells to drive IL-22 responses to skin immunization.

Journal Article

J Exp Med, 213 (10), pp. 2147-66, 2016, ISSN: 0022-1007.

Abstract | Links:

57 entries « ‹ 1 of 6 › »
Signaler des ajouts ou des modifications

Active projects

  • Biology of S100A8 and S100A9 proteins in Human Acute Myeloid Leukemia, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2019-10-01 to 2024-09-30
  • Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31

Recently finished projects

  • Centre de recherche en arthrite de l'Université Laval, Subvention, Institutionnel - BDR, BDR - Entités de recherche en émergence, from 2019-01-01 to 2020-01-31
  • Immunosuppressive function of S100A8 in arthritis., Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2014-07-01 to 2019-06-30
  • The characterization of MICL, a novel negative regulator of the immune response in arthritis., Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2015-07-01 to 2020-06-30
Data provided by the Université Laval research projects registery